AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .
The effect of oxandrolone on voice frequency in growth hormone-treated girls with Turner syndrome.
OBJECTIVES /HYPOTHESIS Ox and rolone ( Ox ) increases height gain but may also cause voice deepening in growth hormone (GH)-treated girls with Turner syndrome ( TS ) . We assessed the effect of Ox on objective and subjective speaking voice frequency in GH-treated girls with TS . STUDY DESIGN A multicenter , r and omized , placebo (Pl)-controlled , double-blind study was conducted . METHODS One hundred thirty-three patients were included and treated with GH ( 1.33 mg/m2/d ) from baseline ,  combined with Pl or Ox  in a low ( 0.03 mg/kg/d ) or conventional ( 0.06 mg/kg/d ) dose from the age of 8 years and estrogens from the age of 12 years . Yearly from starting Ox/Pl until 6 months after discontinuing GH+Ox/Pl , voices were recorded and question naires were completed . RESULTS At start , mean ( ±st and ard deviation [ SD ] ) voice frequency SD score ( SDS ) was high for age ( 1.0±1.2 , P<0.001 ) but normal for height . Compared with GH+Pl , voices tended to lower on GH+Ox 0.03 ( P=0.09 ) and significantly lowered on GH+Ox 0.06 ( P=0.007 ) . At the last measurement , voice frequency SDS was still relatively high in GH+Pl group ( 0.6±0.7 , P=0.002 ) but similar to healthy girls in both GH+Ox groups . Voice frequency became lower than -2 SDS in one patient ( 3 % ) on GH+Ox 0.03 and three patients ( 11 % ) on GH+Ox 0.06 . The percentage of patients reporting subjective voice deepening was similar between the dosage groups . CONCLUSIONS Untreated girls with TS have relatively high-pitched voices . The addition of Ox to GH  decreases voice frequency in a dose-dependent way . Although most voice frequencies remain within the normal range , they may occasionally become lower than -2 SDS , especially on GH+Ox 0.06 mg/kg/d
AUTHORS ' CONCLUSIONS Addition of ox and rolone to the GH therapy led to a modest increase in the final adult height of girls aged up to 18 years with TS .
BACKGROUND The final adult height of untreated girls aged up to 18 years with Turner syndrome ( TS ) is approximately 20 cm shorter compared with healthy females .
Treatment with growth hormone ( GH ) increases the adult height of people with TS .
The effects of adding the and rogen , ox and rolone , in addition to GH are unclear .
Therefore , we conducted this systematic review to investigate the benefits and harms of ox and rolone as an adjuvant therapy for people with TS treated with GH .
OBJECTIVES To assess the effects of ox and rolone on growth hormone-treated girls aged up to 18 years with Turner syndrome .